Game-Changing Diabetes Treatments Are Coming in 2026—Here's What You Need to Know

The diabetes treatment landscape is about to transform dramatically in 2026, with groundbreaking therapies moving closer to approval that could fundamentally change how we manage both type 1 and type 2 diabetes. From the first medication to preserve insulin-producing cells in newly diagnosed patients to revolutionary stem cell treatments and next-generation glucose-lowering drugs, these advances represent the most significant progress in diabetes care in decades.

Will There Finally Be a Treatment to Preserve Beta Cells in Type 1 Diabetes?

The most anticipated approval of 2026 may be Tzield for newly diagnosed type 1 diabetes patients. This would mark the first therapy ever approved to preserve beta cell function in people with stage 3 type 1 diabetes. Most people still have about 10-20% of their insulin-producing beta cells at diagnosis, and research shows Tzield can protect those remaining cells.

Tzield is already approved to treat people in stage 2 type 1 diabetes, where it has shown the ability to delay progression. The next step is preservation of existing beta cells in those who have already been diagnosed. This represents a fundamental shift from simply managing diabetes to actually slowing its progression.

What Revolutionary Stem Cell Treatments Are Moving Forward?

The push toward a functional cure for type 1 diabetes continues to gain serious momentum. Vertex Pharmaceuticals' phase 3 trial using stem cell-derived islet cells is already underway, building on impressive early results where 10 out of 12 people with severe type 1 diabetes became insulin-independent within a year.

Meanwhile, Kriya Therapeutics' adeno-associated virus (AAV) gene therapy trial is gearing up to start later this year. This approach involves delivering insulin and glucokinase genes directly into muscle tissue to help the body control blood sugar independently, potentially eliminating the need for external insulin or immune-suppressing drugs.

What New Diabetes Medications Are Coming in 2026?

Several game-changing medications are expected to receive Food and Drug Administration (FDA) approval in 2026, offering new options for both type 1 and type 2 diabetes management:

• Orforglipron: Lilly's promising oral glucagon-like peptide-1 (GLP-1) medication that acts similarly to injectable drugs like Mounjaro but can be taken as a once-daily pill without food or water restrictions
• CagriSema: Novo Nordisk's combination therapy that pairs semaglutide with cagrilintide, creating a more powerful approach to glucose control and weight management
• Retatrutide: Known as "Triple G," this medication from Lilly mimics three hormones—GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon—showing average weight loss of 28.7% in recent studies
• Once-weekly basal insulin: Both Lilly's efsitora alpha and Novo Nordisk's insulin icodec are moving toward approval, offering a simpler alternative that reduces the burden of daily injections for type 2 diabetes

The data for once-weekly basal insulin looks particularly promising for type 2 diabetes, performing just as well as today's best daily basal insulins with no additional hypoglycemia risk. However, weekly basals caused more hypoglycemia in type 1 diabetes trials, so approval will likely be limited to type 2 diabetes initially.

How Will Diabetes Technology Advance in 2026?

Technology advances are set to make diabetes management more precise and less burdensome. The biggest development will likely be FDA approval of Abbott's continuous ketone monitoring system, which will notify users of elevated ketones before dangerous diabetic ketoacidosis occurs. This technology will also allow people with type 1 diabetes to safely take sodium-glucose cotransporter-2 (SGLT-2) inhibitors like Jardiance or Farxiga.

Medtronic is expanding its automated insulin delivery (AID) lineup with two new insulin pumps: the MiniMed Flex, a small screenless tubed pump already submitted to the FDA, and the MiniMed Fit, a tubeless patch pump expected to be submitted in late summer. Both will run on a new algorithm called Vivera and pair with Simplera Sync and Instinct sensors.

Inhaled insulin is also getting an update. MannKind's application for Afrezza use in children ages 4 to 17 was submitted to the FDA in October, backed by strong phase 3 results. Additionally, new dosing recommendations for Afrezza are on track for FDA approval, moving away from the original conservative one-to-one dosing with rapid-acting insulin.

These advances represent more than incremental improvements—they signal a fundamental shift toward treatments that could slow, stop, or even reverse diabetes progression. While 2026 may not bring a complete cure for type 1 diabetes, the combination of beta cell preservation therapies, stem cell treatments, and advanced technology is bringing us closer to that goal than ever before.